Taurine NEW
| Price | $41 |
| Package | 500mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: Taurine | CAS No.: 107-35-7 |
| Purity: 99.37% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | Taurine |
| Description | Taurine (2-Aminoethanesulfonic acid) is an organic acid widely distributed in animal tissues and is one of the constituents of bile acids. Taurine is involved in a number of processes related to energy expenditure and muscle function, and can treat fatigue and muscles as well as improve immune function. |
| In vitro | METHODS: Primary alveolar epithelial cells from mice were treated with TGF-β1 (1-3 ng/mL) and TD139 (10 μM), and the expression levels of target proteins were detected by Western Blot. RESULTS: TD139 blocked TGF-β1-induced β-catenin phosphorylation. [1] METHODS: FTC-133 and 8505C cells were treated with TD139 (0-100 μM) for 72 h. Cell viability was determined by CCK8 assay. RESULTS: TD139 decreased cell viability in a dose-dependent manner. [2] |
| In vivo | METHODS: To investigate the effect on the fibrotic phase of bleomycin-induced lung injury, TD139 (10 μg) was administered as an endotracheal drip to the lungs of mice with pulmonary fibrosis four times every two days. RESULTS: In the lungs of WT mice treated with TD139, there was a significant reduction in fibrosis and β-catenin activation, as well as a decrease in galectin-3 expression.TD139 significantly reduced the total amount of pulmonary collagen. At the same time, the fibrosis score decreased from 3.8±0.4 to 2.6±0.3. In the absence of bleomycin, TD139 had no effect on fibrosis. [1] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | H2O : 10 mM DMSO : Insoluble |
| Keywords | inhibit | salts | antioxidant | Autophagy | Endogenous Metabolite | antiatherogenic | pressure-lowering | cardiovascular | Inhibitor | Taurine | blood | bile |
| Related Compound Libraries | Bioactive Compound Library | Flavor Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Anti-Cancer Approved Drug Library | Cosmetic Ingredient Compound Library | Human Endogenous Metabolite Library | Bioactive Compounds Library Max | Gut Microbial Metabolite Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $41.00/500mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2024-11-19 | |
| $100.00/1KG |
VIP6Y
|
Hebei Weibang Biotechnology Co., Ltd
|
2024-10-28 | |
| $2.00/500kg |
VIP1Y
|
Aurora Industry Co., Ltd.
|
2024-09-06 | |
| $7.00/1KG |
VIP4Y
|
Hebei Chuanghai Biotechnology Co,.LTD
|
2024-08-20 | |
| $100.00/50kg |
VIP1Y
|
HEBEI SHENGSUAN CHEMICAL INDUSTRY CO.,LTD
|
2024-08-09 | |
| $6.00/1kg |
VIP1Y
|
HebeiShuoshengImportandExportco.,Ltd
|
2024-08-08 | |
| $0.10/1KG |
VIP6Y
|
Shaanxi Dideu Medichem Co. Ltd
|
2024-07-25 | |
| $0.00/1kg |
VIP2Y
|
Hebei Kingfiner Technology Development Co.Ltd
|
2024-06-17 | |
| $0.00/1KG |
VIP4Y
|
Sinoway Industrial co., ltd.
|
2024-06-03 | |
| $4.00/1KG |
VIP1Y
|
Hebei Longbang Technology Co., Ltd
|
2024-05-31 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY